Antitumor and anti-migratory effects of lurbinectedin on B cells from chronic lymphocytic leukemia (CLL) patients.

RISNIK DENISE; PODAZA ENRIQUE; MERCEDES DE LOS RIOS ALICANDU; COLADO ANA; ALMEJÚN MARÍA BELÉN; BEZARES FERNANDO RAIMUNDO; FERNANDEZ GRECCO HORACIO; BORGE MERCEDES; GALMARINI CARLOS; GAMBERALE ROMINA; GIORDANO MIRTA

Congreso; I Meeting LASID, FAIC, SAI 2015; 2015

LASID FAIC y SAI

Chronic lymphocytic leukemia (CLL) isthe most frequent leukemia in adults and, despite recent advancesin therapy, it remains incurable. Novel treatments should affectboth, neoplastic B-cells and protective microenvironment inlymphoid tissues. Lurbinectedin (Lur) is a synthetic alkaloid thatbinds covalently to DNA and is currently in phase I/II clinicaltrials for solid and hematological tumors. The aims of this studywere to evaluate the cytotoxicity of Lur on circulatingmononuclear cells (PBMC) from CLL patients and healthy donorsand to determine if it affects the in vitro migration of leukemic Bcells.